These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1172 related articles for article (PubMed ID: 22867780)
1. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. van Hout B; Janssen MF; Feng YS; Kohlmann T; Busschbach J; Golicki D; Lloyd A; Scalone L; Kind P; Pickard AS Value Health; 2012; 15(5):708-15. PubMed ID: 22867780 [TBL] [Abstract][Full Text] [Related]
2. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801 [TBL] [Abstract][Full Text] [Related]
3. Interim value set for the EQ-5D-5L in Iran using the Crosswalk method. Ameri H; Safari H; Yousefi M; Bagheri Faradonbeh S; Goudarzi R; Soofi M Med J Islam Repub Iran; 2020; 34():121. PubMed ID: 33437717 [No Abstract] [Full Text] [Related]
4. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets. Kularatna S; Chen G; Byrnes J; Scuffham PA Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311 [TBL] [Abstract][Full Text] [Related]
5. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]
6. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study. Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M; J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744 [TBL] [Abstract][Full Text] [Related]
7. Crosswalk EQ-5D-5L Value Set for Slovenia. Prevolnik Rupel V; Ogorevc M Zdr Varst; 2020 Sep; 59(3):189-194. PubMed ID: 32952720 [TBL] [Abstract][Full Text] [Related]
8. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242 [TBL] [Abstract][Full Text] [Related]
9. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663 [TBL] [Abstract][Full Text] [Related]
10. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey. Jankowska A; Młyńczak K; Golicki D Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271 [TBL] [Abstract][Full Text] [Related]
11. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? Feng Y; Devlin N; Herdman M Health Qual Life Outcomes; 2015 Oct; 13():171. PubMed ID: 26489956 [TBL] [Abstract][Full Text] [Related]
12. Mapping EQ-5D-3L to EQ-5D-5L. van Hout BA; Shaw JW Value Health; 2021 Sep; 24(9):1285-1293. PubMed ID: 34452708 [TBL] [Abstract][Full Text] [Related]
13. EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets. Jiang R; Rand K; Kuharic M; Pickard AS Health Qual Life Outcomes; 2022 Sep; 20(1):134. PubMed ID: 36085228 [TBL] [Abstract][Full Text] [Related]
14. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363 [TBL] [Abstract][Full Text] [Related]
15. The EQ-5D-5L is More Discriminative Than the EQ-5D-3L in Patients with Diabetes in Singapore. Wang P; Luo N; Tai ES; Thumboo J Value Health Reg Issues; 2016 May; 9():57-62. PubMed ID: 27881260 [TBL] [Abstract][Full Text] [Related]
16. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values. Selivanova A; Buskens E; Krabbe PFM Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559 [TBL] [Abstract][Full Text] [Related]
17. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698 [TBL] [Abstract][Full Text] [Related]
18. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA. Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280 [TBL] [Abstract][Full Text] [Related]
19. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730 [TBL] [Abstract][Full Text] [Related]
20. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]